Kouvela Marousa, Livanou Maria Effrosyni, Stefanou Dimitra T, Vathiotis Ioannis A, Sarropoulou Fotini, Grammoustianou Maria, Dimakakos Evangelos, Syrigos Nikolaos
Oncology Unit, Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, 11527 Athens, Greece.
First Department of Internal Medicine, Laikon General Hospital, School of Medicine, National Kapodistrian University of Athens, 11527 Athens, Greece.
Cancers (Basel). 2024 Apr 8;16(7):1442. doi: 10.3390/cancers16071442.
The aim of this study was to record and assess the efficacy and safety ofthromboprophylaxis with an intermediate dose of Tinzaparin in lung cancer patients with high thrombotic risk.
This was a non-interventional, single-arm, prospective cohort study of lung cancer patients who received thromboprophylaxis with Tinzaparin 10.000 Anti-Xa IU in 0.5 mL, OD, used in current clinical practice. Enrolled ambulatory patients signed informed consent. Anti-Xa levels were tested.
In total, 140 patients were included in the study, of which 81.4% were males. The histology of the tumor was mainly adenocarcinoma. Lung cancer patients with high thrombotic risk based on tumor, patient, treatment, and laboratory-related factors were enrolled. Only one patient experienced a thrombotic event (0.7%), and 10 patients had bleeding events (7.1%), including only one major event. Anti-Xa levels measured at 10 days and 3 months did not differ significantly between patients who developed hemorrhagic events and those who did not ( = 0.26 and = 0.32, respectively).
Thromboprophylaxis with an intermediate Tinzaparin dose in high thrombotic-risk lung cancer patients is a safe and effective choice for the prevention of VTE.
本研究的目的是记录并评估中剂量替扎肝素对高血栓形成风险肺癌患者进行血栓预防的疗效和安全性。
这是一项针对肺癌患者的非干预性、单臂、前瞻性队列研究，这些患者在当前临床实践中接受0.5 mL、每日一次、剂量为10000抗Xa国际单位的替扎肝素进行血栓预防。纳入的门诊患者签署了知情同意书，并检测了抗Xa水平。
该研究共纳入140例患者，其中81.4%为男性。肿瘤组织学类型主要为腺癌。纳入了基于肿瘤、患者、治疗及实验室相关因素具有高血栓形成风险的肺癌患者。仅1例患者发生血栓事件（0.7%），10例患者发生出血事件（7.1%），其中仅1例为严重事件。发生出血事件的患者与未发生出血事件的患者在第10天和3个月时测得的抗Xa水平无显著差异（分别为P = 0.26和P = 0.32）。
中剂量替扎肝素对高血栓形成风险肺癌患者进行血栓预防是预防静脉血栓栓塞的一种安全有效的选择。
Zotero 插件